Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

fically inhibit the production of VLA-4 could significantly reduce disease activity in RRMS patients as early as 8 weeks. The level of efficacy achieved by ATL/TV1102 is very promising particularly when considering the short duration of dosing within the trial. As an antisense drug ATL/TV1102 will have a different, potentially preferable, safety profile to other drugs that target VLA-4 and therefore presents an exciting future treatment option for RRMS patients."

Mark Diamond, Chief Executive Officer of Antisense Therapeutics, said, "We are delighted to have our ATL/TV1102 Phase IIa trial results presented at such an important scientific meeting on MS. The development of ATL/TV1102 as an MS treatment continues with our partner Teva Pharmaceutical Industries (Teva) and we look forward to the prospect of Teva reporting on ATL/TV1102's future clinical progress. Importantly, the demonstration of significant disease activity with ATL/TV1102 in MS points to the potential of ATL/TV1102 in other disease settings such as autoimmune, inflammation and cancer. It also provides important validation for the application of second-generation antisense drugs outside of cardiovascular and metabolic diseases such as high cholesterol and diabetes where there has been success to date. We believe our results provide important substantiation for the broader clinical application of the second-generation technology."

"We are very encouraged by the data. Not only do they represent promising results for patients with MS, but they also evidence the significant progress we are making in demonstrating the effectiveness, efficiency and the breadth of opportunity of our antisense platform. It's another disease and another tissue where we have great proof-of-concept for antisense drugs," said Stanley Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis. "ATL/TV1102 and ATL's strategic relationship with Teva to move the drug forward further validates our business strategy.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... States will increase to a value of ... driven by expansion in the large direct energy device ... be increasingly adopted due to the advantages they offer ... key findings from Decision Resources Group,s coverage of the ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... May 11, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today ... the 2011 UBS Global Specialty Pharmaceuticals Conference in London ... The presentation will be simultaneously webcast and ...
... Inc. (OTC Bulletin Board: NEPH ), a ... therapeutic applications, infection control, and water purification, today announced ... from the Therapeutic Products Directorate of Health Canada, the ... Ultrafilters (DSU) in Canada to filter out biological contaminants ...
Cached Medicine Technology:Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 2Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 3Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 4
(Date:12/21/2014)... Recently, BambooFlooringChina.com, a famous bamboo lumber supplier, has ... , and launched a bamboo flooring promotion with great ... Jan. 30, 2015. , According to the CEO of ... flooring available today; it has a highly distinctive grain ... Strand woven bamboo is made by a unique manufacturing ...
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring wedding dresses ... new designs in this collection, and all of them ... AngelWeddingDress.com promises to provide the most fashionable designs ... many fashion trends come and go. If ladies have ... AngelWeddingDress.com is ready to assist. , “These new ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading ... same time helping people get their health back. Mission ... to serving those persons in Muskegon County who are unable ... quality of life. Dr. Michael Rykse wanted to do a ... community and he knew he found that when he heard ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Theme ... announced a new intro plugin for Final Cut Pro ... pictures, videos, logos, and more with absolute ease.” Said ... our users the tools needed to easily animate their ... Final Cut Pro X users to animate pictures, videos, ...
(Date:12/20/2014)... is a professional company offering many kinds of ... its new engineered bamboo flooring collection, and announced a ... BambooIndustry.com’s customers come from many countries in the world: ... CEO of the company, the global bamboo flooring market ... years, and the demand for eco-friendly bamboo flooring products ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2
... and drinking plenty of water are the best ways to ... their growth among children, say paediatricians.// ,Kidney stones ... and can cause urinary tract infections. Signs and symptoms of ... in the sides, frequent and painful urination, blood in the ...
... Administering Testosterones can slow down the progression of Alzheimer's ... Testosterone, the primary male sex hormone, is one// in ... androgens. , The findings, published in the ... new insight into the relationship between testosterone loss and ...
... about 'DNA-diets', advertised extensively on the internet, making tall claims ... ,A study, spearheaded by researchers at the Economic and ... the University of Exeter, is the first study of its ... DNA diets are also called 'nutrigenomic' diets that are customized ...
... children in three months in Uttar Pradesh, leaving health authorities ... encephalitis killed at least 400 children in eastern Uttar Pradesh ... the region claiming children as victims. ,'The killer ... a loss as to how we should tackle it,' said ...
... removed from her leg in November, the White House has said.// ... biopsy of a small sore on the shin of her right ... said Monday evening. ,Doctors identified it as a squamous ... ,"Because of Mrs. Bush's early detection and treatment the area ...
... The South Nassau Communities Hospital here has appointed a noted ... is recognised as a leading head and neck surgeon in ... oncology. ,"This is truly a career highlight and I ... medical community in this capacity," Datta said. ...
Cached Medicine News:Health News:Drinking Plenty of Water may Prevent Kidney Stones 2Health News:Increase Testosterone Levels To Slow Down Alzheimer’ 2
... The ESR-10 Manual Rack is ... for determining the erythrocyte sedimentation rate ... minutes using 1.2ml Streck ESR-Vacuum Tubes. ... 10 tubes simultaneously. The ESR-10 Manual ...
... use as a sheath fluid when performing ... of Cytometry Concentrate dilutes to 3L of ... Cubitainers, Streck Cytometry Concentrate reduces heavy lifting, ... compromising performance. Streck Cytometry Concentrate has a ...
... is a stabilized preparation of ... be used as a complete ... positive cells. It is compatible ... gating strategies. CD-Chex CD34 has ...
... A lytic reagent manufactured ... determination of hemoglobin and ... Agent IIIA is manufactured ... the Abbott CELL-DYN® 1700. ...
Medicine Products: